FDA Emphasizes Pre-Submissions For Neuro Devices
Executive Summary
Make pre-submissions early and as complete as possible to ensure speedy review and thorough answers for neurological devices, FDA staff says.
You may also be interested in...
MDUFA IV Takes Shape: A Catalogue Of Draft Commitments
More specific details have emerged about the agreement "in principle" announced last week by FDA and industry negotiators on the next round of the medical device user-fee program, which will extend from fiscal years 2018 through 2022.
Talk Now: FDA Finalizes Guidance On Pre-Market Communications
The guidance, which is very similar to a proposed version from last year, updates the interactive review program, and describes three relatively new points of communication between FDA and a device sponsor during the review process.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.